Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.37 USD | -1.65% | -12.97% | +6.97% |
Mar. 26 | North American Morning Briefing : Markets Steady -2- | DJ |
Mar. 25 | Piper Sandler Adjusts Price Target on ImmunityBio to $5 From $4, Maintains Neutral Rating | MT |
Financials (USD)
Sales 2024 * | 9.68M | Sales 2025 * | 84.68M | Capitalization | 3.62B |
---|---|---|---|---|---|
Net income 2024 * | -459M | Net income 2025 * | -305M | EV / Sales 2024 * | 374 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 42.7 x |
P/E ratio 2024 * |
-7.9
x | P/E ratio 2025 * |
-11.9
x | Employees | 628 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 20.33% |
Latest transcript on ImmunityBio, Inc.
1 day | -1.65% | ||
1 week | -12.97% | ||
Current month | +13.53% | ||
1 month | +18.02% | ||
3 months | +3.07% | ||
6 months | +235.62% | ||
Current year | +6.97% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Adcock
CEO | Chief Executive Officer | 55 | 20-09-30 |
Founder | 71 | 14-11-30 | |
David Sachs
DFI | Director of Finance/CFO | 46 | 19-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 71 | 14-11-30 | |
Cheryl L. Cohen
BRD | Director/Board Member | 58 | 19-05-31 |
Wesley Clark
BRD | Director/Board Member | 78 | 21-02-23 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.04% | 0 M€ | 0.00% | - | |
0.02% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 5.37 | -1.65% | 4,630,603 |
24-03-27 | 5.46 | +6.64% | 5,237,370 |
24-03-26 | 5.12 | -5.88% | 2,950,073 |
24-03-25 | 5.44 | -10.38% | 4,439,565 |
24-03-22 | 6.07 | -1.62% | 5,266,643 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.97% | 3.62B | |
+2.73% | 108B | |
+9.59% | 103B | |
+6.58% | 23.48B | |
-12.59% | 21.93B | |
-3.29% | 19.68B | |
-35.36% | 18.37B | |
-13.29% | 16.33B | |
+4.68% | 13.72B | |
+34.25% | 12.15B |